NASDAQ$MAZE
Maze Therapeutics Inc · Q2 2026 earnings
Q2 2026 earnings · · After market close
Briefing
Maze Therapeutics Inc reported a net loss of $44.7 million for the second quarter of 2026.
The company continued advancing its lead clinical programs MZE829 and MZE782 with increased R&D investment. Research and development expenses rose to $34.9 million while maintaining a strong liquidity position of $494.9 million in cash, cash equivalents and marketable securities. The company completed an equity offering in April 2026 raising net proceeds of approximately $144.6 million.
- Reported net loss of $44.7 million ($0.76 per share) for Q2 2026, compared to $33.7 million in Q2 2025
- R&D expenses increased 24% year-over-year to $34.9 million driven by clinical advancement of MZE829 and MZE782
- Cash, cash equivalents and marketable securities totaled $494.9 million at quarter end
- Completed underwritten registered offering in April 2026 raising $144.6 million in net proceeds
Headline financials
Revenue & EPS history
Maze Therapeutics Inc · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+38.8%
Avg return
30 days after
67%
2 / 3 earnings
Positive
+2.0%
Q2 2025
Best reaction
-2.1%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.9% | +0.4% | -5.6% | |
| Q3 2025 | -2.1% | +6.6% | +37.8% | |
| Q2 2025 | +2.0% | +0.2% | +84.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro